Literature DB >> 16391183

Comparison of 2-dimensional and 3-dimensional acquisition for 18F-FDG PET oncology studies performed on an LSO-based scanner.

Martin A Lodge1, Ramsey D Badawi, Richard Gilbert, Pablo E Dibos, Bruce R Line.   

Abstract

UNLABELLED: Three-dimensional (3D) PET acquisition has the potential to reduce image noise but the advantage of 3D PET for studies outside the brain has not been well established. To compare the performance of 2-dimensional (2D) and 3D acquisition for whole-body (18)F-FDG applications, a series of patient studies were performed using a lutetium oxyorthosilicate (LSO)-based tomograph.
METHODS: Comparative 2D and 3D images were acquired for 27 oncology patients using an LSO-based tomograph. Data acquisition (350-650 keV, 6 ns) started 99 +/- 12 min (mean +/- SD) after injection of 624 +/- 76 MBq (18)F-FDG. Bias caused by tracer redistribution and decay was eliminated by acquiring dynamic data over a single-bed position using a protocol that alternated between septa-in and septa-out modes (2D, 3D, 2D, 3D, 2D, 3D). Frames were combined to form 8 statistically independent sinograms: four 2D replicates (105 s) and four 3D replicates (90 s). The different frame durations in 2D and 3D compensated for the different number of overlapping bed positions required for an 85-cm whole-body study. Images were reconstructed with either 2D or fully 3D ordered-subsets expectation maximization (2 iterations and 8 subsets; 2D 6-mm gaussian, 3D 5- and 6-mm gaussian). Image target-to-background ratio was assessed by dividing the lesion maximum by the mean within a neighboring background region. Image noise was assessed by applying background regions of interest to the replicate images and calculating the within-patient coefficient of variation.
RESULTS: The difference in target-to-background ratio between the 2D and 3D images, when they were filtered with 6-mm and 5-mm gaussian filters, respectively, was not highly statistically significant (P = 0.16). The mean ratio of 3D to 2D image values was 0.94 with 95% limits of agreement of 0.63-1.41. The within-patient coefficients of variation for the 2D and 3D images were 13% +/- 15% and 9% +/- 10%, respectively (P = 0.0005).
CONCLUSION: Under conditions of matched target to-to-background ratios, the 3D mode was found to produce images with significantly less variability than the 2D mode. These data provide support for the use of 3D acquisition with LSO detectors to reduce scan times in whole-body (18)F-FDG applications.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16391183

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  5 in total

1.  Putting 'clear' into nuclear medicine: a decade of PET/CT development.

Authors:  Thomas Beyer; David W Townsend
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-08       Impact factor: 9.236

Review 2.  Dynamic whole-body PET imaging: principles, potentials and applications.

Authors:  Arman Rahmim; Martin A Lodge; Nicolas A Karakatsanis; Vladimir Y Panin; Yun Zhou; Alan McMillan; Steve Cho; Habib Zaidi; Michael E Casey; Richard L Wahl
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-09-29       Impact factor: 9.236

3.  Accuracy of 3D acquisition mode for myocardial FDG PET studies using a BGO-based scanner.

Authors:  Arno P van der Weerdt; Ronald Boellaard; Frans C Visser; Adriaan A Lammertsma
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-02-27       Impact factor: 9.236

4.  Time-related study on external exposure dose of 2-deoxy-2-[F-18]fluoro-D-glucose PET for workers' safety.

Authors:  Yasuyuki Takahashi; Shota Hosokawa; Takakiyo Tsujiguchi; Satoru Monzen; Takao Kanzaki; Koji Shirakawa; Ayaka Nemoto; Hayato Ishimura; Noboru Oriuchi
Journal:  Radiol Phys Technol       Date:  2019-12-12

Review 5.  Real time dynamic imaging and current targeted therapies in the war on cancer: a new paradigm.

Authors:  Ramasamy Paulmurugan; Bryan Oronsky; Chad F Brouse; Tony Reid; Susan Knox; Jan Scicinski
Journal:  Theranostics       Date:  2013-05-25       Impact factor: 11.556

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.